Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on ANI Pharmaceuticals (ANIP – Research Report). The associated price target remains the same with $82.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Faisal Khurshid has given his Buy rating due to a combination of factors that highlight ANI Pharmaceuticals as a promising investment opportunity. The company operates within the stable US pharmaceutical market, with a strong focus on generics and branded specialty products, which positions it as a reliable entity amidst market uncertainties such as tariffs and fluctuating interest rates. ANIP’s diversified portfolio, including the successful Cortrophin Gel, underscores its potential for sustained growth.
Moreover, ANIP’s financial outlook is robust, with projections indicating significant revenue and EBITDA growth by 2025. The company’s strategic acquisitions, like that of Alimera, further enhance its growth prospects in the Rare Disease segment, expected to surpass its generics business. This combination of stable cash flow, strategic diversification, and strong growth trajectory supports Khurshid’s optimistic Buy rating for ANIP.
Khurshid covers the Healthcare sector, focusing on stocks such as Pliant Therapeutics, aTyr Pharma, and Trevi Therapeutics. According to TipRanks, Khurshid has an average return of 22.2% and a 40.00% success rate on recommended stocks.
In another report released on March 26, Jefferies also reiterated a Buy rating on the stock with a $80.00 price target.